Fig. 13.

Cochlear histopathology quantification after the 4 × 3 treatment protocol. a OHC counts after the 4 × 3 protocol. As expected, OHC loss in the cisplatin-treated group (n = 6) was significantly greater than the saline group (n = 7) across the regions of the basilar membrane that were evaluated. b IHC counts demonstrated no significant differences between the cisplatin and control groups. c Presynaptic ribbons on the IHCs were also reduced in the cisplatin-treated group. *p < 0.05, **p < 0.01, and ***p < 0.001. Data shown are the means ± 1 SEM